N

P

NUCIFORO , Paolo

Last name: NUCIFORO

First name: Paolo

2019 (v1)

Publication

Metadata-only

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Saura, Cristina Hlauschek, Dominik Oliveira, Mafalda

Background: Endocrine therapy-based neoadjuvant treatment for luminal breast cancer allows efficient testing of new combinations before surgery. The activation of the phosphatidylinositol-3-kinase (PI3K) pathway is a known mechanism of resistance to endocrine therapy. Taselisib is an oral, selective PI3K inhibitor with enhanced activity against...

Uploaded on: March 27, 2023